Malignant bowel obstruction in advanced ovarian cancer

Emma Dean, Leila Khoja, Andrew Clamp, Gordon C Jayson, Dilly Goonetilleke, Alicia M Conway, Jurjees Hasan

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


AIM: Malignant bowel obstruction (MBO) in ovarian cancer is poorly understood.

METHODS: This retrospective cohort study analyzed 129 patients with ovarian cancer and MBO.

RESULTS: At presentation, 69 (53%) had platinum-resistant, 37 (29%) platinum-sensitive and 23 (18%) chemotherapy-naive disease. In patients receiving chemotherapy following the MBO episode, median overall survival (OS) was 107 days for chemotherapy-naive patients compared with 83 and 86 for platinum-sensitive or platinum-resistant patients (p = 0.98). OS was inferior for best supportive care (45 days) compared with chemotherapy (152 days) or surgery (124 days; p < 0.001). The Manchester Bowel Obstruction Score using Eastern Cooperative Oncology Group and obstruction level discriminated patients by median OS of 181 days (neither) versus 98 days (one) versus 42 days (both; p < 0.01).

CONCLUSION: The Manchester Bowel Obstruction Score may aide treatment stratification.

Original languageEnglish
Pages (from-to)513-521
Number of pages9
JournalFuture Oncology
Issue number6
Publication statusPublished - Mar 2017


  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Disease Management
  • Female
  • Humans
  • Intestinal Obstruction/diagnosis
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasm Staging
  • Ovarian Neoplasms/complications
  • Proportional Hazards Models
  • Retrospective Studies
  • Treatment Outcome


Dive into the research topics of 'Malignant bowel obstruction in advanced ovarian cancer'. Together they form a unique fingerprint.

Cite this